缺乏XIII因子:实验室,分子和临床方面
Akbar Dorgalaleh1, Sina Jozdani2, Masoumeh Kiani Zadeh3
1Hamin Pazhuhan Tis Institute, Tehran, Iran.
Seminars in thrombosis and hemostasis
|November 29, 2024
概括
缺乏XIII因子 (FXIII) 可能导致严重出血. 考虑到个体因素的个性化治疗是治疗这种罕见的出血障碍的最佳方式,特别是对女性异构性FXIII-A缺乏症的治疗.
科学领域:
- 血液学 血液学 血液学
- 罕见的出血障碍 罕见的出血障碍
- 凝血因子缺陷 凝血因子缺陷
背景情况:
- XIII-A因子 (FXIII-A) 缺乏是一种罕见的出血障碍,患病率很高,通常是由于内出血,出血和流产.
- 严重的FXIII-B缺陷具有较温和的表型,而异合体的FXIII-A缺陷影响0.8-3.5%并且在静血挑战期间带来风险,特别是在女性身上.
- 在F13A和F13B基因中存在超过200种突变,大多数是错误的,具有有限的基因型-表型相关性,但因子活性和临床严重性之间存在联系.
研究的目的:
- 审查临床表现,遗传基础和因子XIII缺乏症的治疗策略.
- 突出预测出血模式的挑战和需要量身定制的治疗方法.
- 强调个性化,基于药理动力学的替代疗法的重要性,以优化治疗疗效.
主要方法:
- 关于XIII因子缺乏的现有文献的综述.
- 对基因型-表型相关性和因子活性水平的分析.
- 评估当前的治疗方案和个性化治疗的理由.
主要成果:
- 严重的FXIII-A缺乏症需要初级预防;异合体的FXIII-A缺乏症和FXIII-B缺乏症往往需要按需治疗,特别是在静血挑战期间患有FXIII-A缺乏症的女性.
- 基因型不能可靠地预测表型,但因子活性与临床严重程度相关.
- 以药理动力学为基础的个性化替代疗法,考虑到各种患者特异性因素,是最佳的治疗策略.
结论:
- 管理XIII因子缺乏症需要仔细考虑缺乏症类型,严重程度和个体患者的特征.
- 个性化治疗优化了因子XIII缺乏症的治疗疗效,超出了一般指导方针.
- 对优化基于药理动力学的疗法进行进一步的研究可以改善FXIII缺乏症患者的治疗结果.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
623
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
623
Extrinsic and Intrinsic Pathways of Hemostasis
5.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.6K
Coagulation
4.8K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
4.8K
Disorders of Hemostasis
710
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
710
Clot Retraction and Fibrinolysis
4.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.1K


